FY2025 · ended Dec 31, 2025 · Revenue $411.33M, +14.7% YoY · Filed Feb 25, 2026
Innoviva, Inc. (INVA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $411.3 million and net income of $271.2 million. Free cash flow was $195.8 million. As of Sep 30, 2026 it held $986.2 million in cash and investments and $269.9 million in total debt.
Revenue (TTM)
$438.32M
+12.8% vs year-ago TTM
Net income (TTM)
$193.44M
+51.9% vs year-ago TTM
Operating cash flow (TTM)
$183.47M
-9.0% vs year-ago TTM
Free cash flow (TTM)
$182.51M
-9.0% vs year-ago TTM
EPS (TTM)
$2.52
+78.6% vs year-ago TTM
Dividend per share
$0.00
Shares outstanding
74.07M
+18.2% vs prior year
Net cash
$716.36M
as of Sep 30, 2026
Operating margin
38.8%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INVA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Burlingame, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1080014
- Former names
- THERAVANCE INC (until Dec 7, 2015); ADVANCED MEDICINE INC (until Aug 2, 2000)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $411.3M | $358.7M | $310.5M | $331.3M | $391.9M |
| Operating income | $163.7M | — | — | — | $375.1M |
| Net income | $271.2M | $23.4M | $179.7M | $220.3M | $368.8M |
| Diluted EPS | $3.30 | $0.36 | $2.20 | $2.37 | $2.87 |
| Operating cash flow | $196.9M | $188.7M | $141.1M | $201.7M | $363.8M |
| Free cash flow | $195.8M | $188.4M | $140.7M | $201.7M | $363.8M |
| Total assets | $1.6B | $1.3B | $1.2B | $1.2B | $926.4M |
| Stockholders' equity | $1.2B | — | — | $565.8M | $414.7M |
| Cash and investments | $955.4M | $646.6M | $637.9M | $654.9M | $685.4M |
| Total debt | $269.0M | $451.1M | $449.1M | $544.1M | $394.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Officer or director change
|
May 18, 2026 | May 12, 2026 |
| 10-Q | Quarterly report | May 6, 2026 | Mar 31, 2026 |
All 1002 Innoviva, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.